In human melanoma patients Ipilimumab (anti-CTLA4) therapy was the first one to improve patient survival at stage III/IV significantly reducing G-MDSC frequency followed by the reduction of ArgI producing CD3− cells [171]. The gene discussed is LNCARGI; the disease is melanoma.